Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T00:57:18.949Z Has data issue: false hasContentIssue false
  • English
  • Français

The Treatment of Neuropathic Pain

Published online by Cambridge University Press:  07 November 2014

Roy Freeman
Get access Rights & Permissions [Opens in a new window]

Abstract

Neuropathic pain is responsible for a significant amount of the morbidity associated with generalized and focal peripheral neuropathies. It is a consequence of alterations in neuronal function, chemistry, and structure that occur secondary to nerve injury. These manifestations of neuronal plasticity occur in the peripheral nerve, spinal cord, and brain. A variety of agents from diverse pharmacologic classes, the so-called adjuvant analgesics, have been used to treat neuropathic pain. These include antidepressants, first- and second-generation anticonvulsants, antiarrhythmic agents, topical agents, N-methyl-D-aspartate receptor antagonists, and opioid analgesics. The use of these adjuvant analgesics, either alone or in combination, should result in the alleviation of neuropathic pain in most patients. Recent advances in the understanding of pain mechanisms at multiple central nervous system levels should pave the way toward more effective treatment modalities.

Type
Review Articles
Information
CNS Spectrums , Volume 10 , Issue 9 , September 2005 , pp. 698 - 706
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Basbaum, Al, Jessell, TM. The perception of pain. In: Kandel, ER, Schwartz, JS, Jessell, TM, eds. Principles of Neural Science. New York, NY: McGraw-Hill; 2000.Google Scholar
2.Woolf, CJ, Mannion, RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959–1964.Google Scholar
3.Julius, D, Basbaum, Al. Molecular mechanisms of nociception. Nature. 2001;413:203–210.Google Scholar
4.Snider, WD, McMahon, SB. Tackling pain at the source: new ideas about nociceptors. Neuron. 1998;20:629–632.CrossRefGoogle ScholarPubMed
5.Fields, HL, Basbaum, Al. Central nervous system mechanisms of pain modulation. In: Wall, PD, Melzack, R, eds. Textbook of Pain. New York, NY: Churchill Livingstone; 1999.Google Scholar
6.Rasmussen, PV, Sindrup, SH, Jensen, TS, Bach, FW. Symptoms and signs in patients with suspected neuropathic pain. Pain. 2004;110:461–469.CrossRefGoogle ScholarPubMed
7.Baron, R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. 2000;16:S12–S20.Google Scholar
8.Waxman, SG, Cummins, TR, Dib-Hajj, S, Fjell, J, Black, JA. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve. 1999;22:1177–1187.3.0.CO;2-P>CrossRefGoogle ScholarPubMed
9.Craner, MJ, Klein, JP, Renganathan, M, Black, JA, Waxman, SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol. 2002;52:786–792.Google Scholar
10.Hains, BC, Saab, CY, Klein, JP, Craner, MJ, Waxman, SG. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci. 2004;24:4832–4839.Google Scholar
11.Woolf, CJ, Salter, MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765–1769.CrossRefGoogle ScholarPubMed
12.Taylor, CJ, Gee, NS, Su, TZ, et al.A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233–249.Google Scholar
13.Karst, M, Salim, K, Burstein, S, Conrad, I, Hoy, L, Schneider, U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757–1762.CrossRefGoogle ScholarPubMed
14.Petrenko, AB, Yamakura, T, Baba, H, Shimoji, K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108–1116.CrossRefGoogle ScholarPubMed
15.Wallace, MS, Rowbotham, MC, Katz, NP, et al.A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology. 2002;59:1694–1700.Google Scholar
16.Baba, H, Ji, RR, Kohno, T, et al.Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci. 2003;24:818–830.Google Scholar
17.Hwang, JH, Yaksh, TL. The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain. 1997;70:15–22.CrossRefGoogle Scholar
18.Kingery, WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes [see comments]. Pain. 1997;73:123–139.CrossRefGoogle ScholarPubMed
19.Sindrup, SH, Jensen, TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400.CrossRefGoogle ScholarPubMed
20.Sindrup, SH, Jensen, TS. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000;55:915–920.CrossRefGoogle ScholarPubMed
21.Gorelick, AB, Koshy, SS, Hooper, FG, Bennett, TC, Chey, WD, Hasler, WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 1998;275:G460–G466.Google Scholar
22.Kishore-Kumar, R, Max, MB, Schafer, SC, et al.Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 1990;47:305–312.Google Scholar
23.Max, MB, Schafer, SC, Culnane, M, Smoller, B, Dubner, R, Gracely, RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988;38:1427–1432.CrossRefGoogle Scholar
24.McQuay, HJ, Tramer, M, Nye, BA, Carroll, D, Wiffen, PJ, Moore, RA. A systematic review of antidepressants in neuropathic pain [see comments]. Pain. 1996;68:217–227.CrossRefGoogle ScholarPubMed
25.Vrethem, M, Boivie, J, Arnqvist, H, Holmgren, H, Lindstrom, T, Thorell, LH. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain. 1997;13:313–323.CrossRefGoogle ScholarPubMed
26.Davis, JL, Lewis, SB, Gerich, JE, Kaplan, RA, Schultz, TA, Wallin, JD. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA. 1977;238:2291–2292.CrossRefGoogle ScholarPubMed
27.Max, MB, Culnane, M, Schafer, SC, et al.Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589–596.Google Scholar
28.Max, MB, Kishore-Kumar, R, Schafer, SC, et al.Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45:3–9.Google Scholar
29.Max, MB, Lynch, SA, Muir, J, Shoaf, SE, Smoller, B, Dubner, R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256.CrossRefGoogle ScholarPubMed
30.Max, MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol. 1994;35(suppl):S50–S53.CrossRefGoogle ScholarPubMed
31.Mendel, CM, Klein, RF, Chappell, DA, et al.A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA. 1986;255:637–639.CrossRefGoogle ScholarPubMed
32.Watson, CP, Evans, RJ, Reed, K, Merskey, H, Goldsmith, L, Warsh, J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982;32:671–673.Google Scholar
33.Watson, CP, Evans, RJ. A comparative trial of amitriptyline and zimelidine in postherpetic neuralgia. Pain. 1985;23:387–394.Google Scholar
34.Sindrup, SH, Gram, LF, Skjold, T, Grodum, E, Brosen, K, Beck-Nielsen, H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol. 1990;30:683–691.Google Scholar
35.Jackson, WK, Roose, SP, Glassman, AH. Cardiovascular toxicity of antidepressant medications. Psychopathology. 1987;20(suppl 1):64–74.Google Scholar
36.Glassman, AH, Roose, SP, Bigger, JT Jr.The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA. 1993;269:2673–2675.Google Scholar
37.Roose, SP, Glassman, AH, Dalack, GW. Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry. 1989;50(suppl):12–16.Google Scholar
38.Sindrup, SH, Bjerre, U, Dejgaard, A, Brosen, K, Aaes-Jorgensen, T, Gram, LE. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992;52:547–552.Google Scholar
39.Sindrup, SH, Gram, LF, Br:sen, K, Eshoj, O, Mogensen, EEThe selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42:135–144.CrossRefGoogle ScholarPubMed
40.Semenchuk, MR, Sherman, S, Davis, B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57:1583–1588.CrossRefGoogle ScholarPubMed
41.Sindrup, SH, Bach, FW, Madsen, C, Gram, LF, Jensen, TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60:1284–1289.Google Scholar
42.Rowbotham, MC, Goli, V, Kunz, NR, Lei, D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697–706.Google Scholar
43.Vaishnavi, SN, Nemeroff, CB, Plott, SJ, Rao, SG, Kranzler, J, Owens, MJ. Milnacipran: a comparative analysis of human monoamine uptake, and transporter binding affinity. Biol Psychiatry. 2004;55:320–322.Google Scholar
44.Beique, JC, Lavoie, N, de Montigny, C, Debonnel, G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998;349:129–132.Google Scholar
45.Goldstein, DJ, Lu, Y, Detke, MJ, Hudson, J, Iyengar, S, Demitrack, MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45:17–28.Google Scholar
46.Iyengar, S, Webster, AA, Hemrick-Luecke, SK, Xu, JY, Simmons, RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311:576–584.Google Scholar
47.Goldstein, DJ, Lu, Y, Detke, MJ, Lee, TC, Iyengar, S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118.Google Scholar
48.Rull, JA, Quibrera, R, Gonzalez-Millan, H, Lozano, CO. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969;5:215–218.Google Scholar
49.Saudek, CD, Werns, S, Reidenberg, MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 1977;22:196–199.Google Scholar
50.Chadda, VS, Mathur, MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India. 1978;26:403–406.Google ScholarPubMed
51.Kochar, DK, Rawat, N, Agrawal, RP, et al.Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM. 2004;97:33–38.Google Scholar
52.Kochar, DK, Jain, N, Agarwal, RP, Srivastava, T, Agarwal, P, Gupta, S. Sodium valproate in the management of painful neuropathy in type 2 diabetes—a randomized placebo controlled study. Acta Neurol Scand. 2002;106:248–252.Google Scholar
53.Otto, M, Bach, FW, Jensen, TS, Sindrup, SH. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology. 2004;62:285–288.Google Scholar
54.Backonja, M, Beydoun, A, Edwards, KR, et al.Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial [see comments]. JAMA. 1998;280:1831–1836.CrossRefGoogle ScholarPubMed
55.Gorson, KC, Schott, C, Herman, R, Ropper, AH, Rand, WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251–252.Google Scholar
56.Rice, AS, Maton, S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215–224.Google Scholar
57.Rowbotham, M, Harden, N, Stacey, B, Bernstein, P, Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial [see comments]. JAMA. 1998;280:1837–1842.Google Scholar
58.Caraceni, A, Zecca, E, Bonezzi, C, et al.Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909–2917.Google Scholar
59.Bone, M, Critchley, P, Buggy, DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27:481–486.Google ScholarPubMed
60.Pandey, CK, Bose, N, Garg, G, et al.Gabapentin for the treatment of pain in guillain-barre syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95:1719–1723.Google Scholar
61.Ahn, SH, Park, HW, Lee, BS, et al.Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. Spine. 2003;28:341–346.Google Scholar
62.Tai, Q, Kirshblum, S, Chen, B, Millis, S, Johnston, M, DeLisa, JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100–105.Google Scholar
63.Morello, CM, Leckband, SG, Stoner, CP, Moorhouse, DF, Sahagian, GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931–1937.Google Scholar
64.McLean, MJ. Gabapentin. Epilepsia. 1995;36(suppl 2):S73–S86.Google Scholar
65.Sabatowski, R, Galvez, R, Cherry, DA, et al.Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35.CrossRefGoogle ScholarPubMed
66.Dworkin, RH, Corbin, AE, Young, JP Jr, et al.Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274–1283.Google Scholar
67.Rosenstock, J, Tuchman, M, LaMoreaux, L, Sharma, U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–638.CrossRefGoogle ScholarPubMed
68.Lesser, H, Sharma, U, LaMoreaux, L, Poole, RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–2110.Google Scholar
69.Gee, NS, Brown, JP, Dissanayake, VU, Offord, J, Thurlow, R, Woodruff, GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768–5776.Google Scholar
70.Field, MJ, Hughes, J, Singh, L. Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol. 2000;131:282–286.Google Scholar
71.Fehrenbacher, JC, Taylor, CP, Vasko, MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105:133–141.Google Scholar
72.Barber, LA, Vasko, MR. Activation of protein kinase C augments peptide release from rat sensory neurons. J Neurochem. 1996;67:72–80.Google Scholar
73.Cheung, H, Kamp, D, Harris, E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 1992;13:107–112.Google Scholar
74.Simpson, DM, Olney, R, McArthur, JC, Khan, A, Godbold, J, Ebel-Frommer, K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115–2119.Google Scholar
75.Simpson, DM, McArthur, JC, Olney, R, et al.Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508–1514.Google Scholar
76.Eisenberg, E, Lurie, Y, Braker, C, Daoud, D, Ishay, A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–509.Google Scholar
77.Vestergaard, K, Andersen, G, Gottrup, H, Kristensen, BT, Jensen, TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184–190.Google Scholar
78.Finnerup, NB, Sindrup, SH, Bach, FW, Johannesen, IL, Jensen, TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375–383.CrossRefGoogle ScholarPubMed
79.Shank, RP, Gardocki, JF, Streeter, AJ, Maryanoff, BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3–S9.Google Scholar
80.Thienel, U, Neto, W, Schwabe, SK, Vijapurkar, U; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110:221–231.Google Scholar
81.Raskin, P, Donofrio, PD, Rosenthal, NR, et al.Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63:865–873.CrossRefGoogle ScholarPubMed
82.Dodgson, SJ, Shank, RP, Maryanoff, BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(suppl 1):S35–S39.Google Scholar
83.Beydoun, A, Kobetz, SA, Carrazana, EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain. 2004;20:174–178.Google Scholar
84.Wamil, AW, Schmutz, M, Portet, C, Feldmann, KF, McLean, MJ. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol. 1994;271:301–308.CrossRefGoogle ScholarPubMed
85.McLean, MJ, Schmutz, M, Wamil, AW, Olpe, HR, Portet, C, Feldmann, KF. Oxcarbazepine: mechanisms of action. Epilepsia. 1994;35(suppl 3):S5–S9.Google Scholar
86.Stracke, H, Meyer, UE, Schumacher, HE, Federlin, K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care. 1992;15:1550–1555.Google Scholar
87.Galer, BS, Harle, J, Rowbotham, MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage. 1996;12:161–167.Google Scholar
88.Oskarsson, P, Ljunggren, JG, Lins, PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care. 1997;20:1594–1597.Google Scholar
89.Dejgard, A, Petersen, P, Kastrup, J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet. 1988;1:9–11.CrossRefGoogle ScholarPubMed
90.Wright, JM, Oki, JC, Graves, L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother. 1997;31:29–34.Google Scholar
91.Jarvis, B, Coukell, AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs. 1998;56:691–707.Google Scholar
92.Kieburtz, K, Simpson, D, Yiannoutsos, C, et al.A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998;51:1682–1688.Google Scholar
93.Simone, DA, Nolano, M, Johnson, T, Wendelschafer-Crabb, G, Kennedy, WR. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci. 1998;18:8947–8959.Google Scholar
94.Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med. 1991;151:2225–2229.Google Scholar
95.Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes Care. 1992;15:159–165.Google Scholar
96.Bernstein, JE, Korman, NJ, Bickers, DR, Dahl, MV, Millikan, LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21:265–270.Google Scholar
97.Biesbroeck, R, Bril, V, Hollander, P, et al.A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther. 1995;12:111–120.Google Scholar
98.Tandan, R, Lewis, GA, Badger, GB, Fries, TJ. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care. 1992;15:15–18.Google Scholar
99.Watson, CP, Evans, RJ, Watt, VR. Post-herpetic neuralgia and topical capsaicin. Pain. 1988;33:333–340.CrossRefGoogle ScholarPubMed
100.Watson, CP, Tyler, KL, Bickers, DR, Millikan, LE, Smith, S, Coleman, E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510–526.Google Scholar
101.Galer, BS, Rowbotham, MC, Perander, J, Friedman, E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533–538.Google Scholar
102.Rowbotham, MC, Davies, PS, Fields, HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37:246–253.Google Scholar
103.Rowbotham, MC, Davies, PS, Verkempinck, C, Galer, BS. Lidocaine patch: doubleblind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39–44.Google Scholar
104.Barbano, RL, Herrmann, DN, Hart-Gouleau, S, Pennella-Vaughan, J, Lodewick, PA, Dworkin, RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61:914–918.Google Scholar
105.Harati, Y, Gooch, C, Swenson, M, et al.Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842–1846.Google Scholar
106.Sindrup, SH, Andersen, G, Madsen, C, Smith, T, Brosen, K, Jensen, TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999;83:85–90.Google Scholar
107.Cohen, KL, Lucibello, FE, Chomiak, M. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy [see comments]. Diabetes Care. 1990;13:1074–1077.Google Scholar
108.Sindrup, SH, Madsen, C, Brosen, K, Jensen, TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther. 1999;66:636–641.Google Scholar
109.Raffa, RB, Friderichs, E, Reimann, W, Shank, RP, Codd, EE, Vaught, JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260:275–285.Google Scholar
110.Gimbel, JS, Richards, P, Portenoy, RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003;60:927–934.CrossRefGoogle ScholarPubMed
111.Watson, CP, Moulin, D, Watt-Watson, J, Gordon, A, Eisenhoffer, J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71–78.Google Scholar
112.Watson, CP, Babul, N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837–1841.Google Scholar
113.Raja, SN, Haythornthwaite, JA, Pappagallo, M, et al.Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59:1015–1021.Google Scholar
114.Eisenberg, E, Kleiser, A, Dortort, A, Haim, T, Yarnitsky, D. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain. 1998;2:321–327.Google Scholar
115.Maier, C, Dertwinkel, R, Mansourian, N, et al.Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain. 2003;103:277–283.Google Scholar
116.Nikolajsen, L, Gottrup, H, Kristensen, AG, Jensen, TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg. 2000;91:960–966.Google Scholar
117.Sang, CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage. 2000;19:S21–S25.Google Scholar
118.Sang, CN, Booher, S, Gilron, I, Parada, S, Max, MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology. 2002;96:1053–1061.Google Scholar
119.Amin, P, Sturrock, ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med. 2003;20:114–118.CrossRefGoogle ScholarPubMed
120.Pud, D, Eisenberg, E, Spitzer, A, Adler, R, Fried, G, Yarnitsky, D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain. 1998;75:349–354.Google Scholar
121.Nelson, KA, Park, KM, Robinovitz, E, Tsigos, C, Max, MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212–1218.Google Scholar
122.Gilron, I, Booher, SL, Rowan, MS, Smoller, MS, Max, MB. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology. 2000;55:964–971.Google Scholar